This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising.
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) announced its placement in a BioMedWire editorial examining the company’s Lucid-MS drug candidate and its recent FDA clearance to begin a phase 2 clinical trial. The editorial, “A Micro-Cap Biotech Just Cleared a Milestone Most Never Reach,” highlights Lucid-MS as a patented, first-in-class candidate designed to protect and potentially repair the myelin sheath rather than target the immune system and notes that the milestone has drawn a new buy rating from Wall Street analysts.
To view the full press release, visit https://nnw.fm/MLUtd
NOTE TO INVESTORS: The latest news and updates relating to QNTM are available in the company’s newsroom at https://nnw.fm/QNTM
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer